Nothing really new. A lot hangs on the Supreme Court.
• Affirmed at Baa2; Outlook remains Negative.
• Over next 12-18 months Adj Gross Debt/EBITDA could go <4.0x (from 4.7x)
• Xarelto (already) and Eyelea (from Nov 25) loss of exclusivity are a drag. Cost of replacing drup pipeline is a constraint on deleveraging.
• SCOTUS may opine on the Durnell glyphosate case. Bayer should receive a ruling by June/July 2026. If successful it would be a big positive. Absent a positive ruling, the rating would be cut almost immediately.
Find more articles and bullets on these widgets:
JGBs rallied sharply alongside global bond markets Friday, piercing mid-week resistance in the process. The first important resistance to watch is 141.48, the May 2 high. A break of this level would be viewed as an early bullish signal. A return lower would signal scope for an extension towards 136.57, a Fibonacci projection.
A short-term bullish corrective phase in USDCAD remains in play despite sharp weakness Friday. On the recent run higher, price traded through the 50-day EMA at 1.3739 and this has been followed by a break of resistance at 1.3798, the Jun 23 high. Clearance of 1.3798 represents an important short-term bullish development, signalling scope for a stronger recovery. Sights are on 1.3920 next, the May 21 high. On the downside, initial firm support to watch lies at 1.3716, the 20-day EMA.
Executive Summary